WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of ruxolitinib, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of prurigo nodularis.

2. The use of claim 1, wherein the ruxolitinib, or a pharmaceutically acceptable salt thereof, is ruxolitinib phosphate.

3. The use of claim 1, wherein the ruxolitinib, or a pharmaceutically acceptable salt thereof, is to be administered topically to an affected skin area.

4. The use of claim 1, wherein the ruxolitinib, or a pharmaceutically acceptable salt thereof, is to be administered as a topical formulation.

5. The use of claim 4, wherein the topical formulation is to be administered as a topical formulation comprising about 0.1% to about 3% of the ruxolitinib, or the pharmaceutically acceptable salt thereof, on a free base basis.

6. The use of claim 4, wherein the topical formulation is to be administered as a topical formulation comprising about 0.5% to about 1.5% of the ruxolitinib, or the pharmaceutically acceptable salt thereof, on a free base basis.

7. The use of claim 4, wherein the topical formulation is to be administered as a topical formulation comprising about 0.75% to about 1.5% of the ruxolitinib, or the pharmaceutically acceptable salt thereof, on a free base basis.

8. The use of claim 4, wherein the topical formulation is to be administered as a topical formulation comprising about 0.75% of the ruxolitinib, or the pharmaceutically acceptable salt thereof, on a free base basis.

9. The use of claim 4, wherein the topical formulation is to be administered as a topical formulation comprising about 1% of the ruxolitinib, or the pharmaceutically acceptable salt thereof, on a free base basis.

10. The use of claim 4, wherein the topical formulation is to be administered as a topical formulation comprising about 1.5% of the ruxolitinib, or the pharmaceutically acceptable salt thereof, on a free base basis.

11. The use of claim 4, wherein the topical formulation is to be administered twice per day (BID).

12. The use of claim 4, wherein the topical formulation is to be administered once per day (QD).

13. The use of claim 4, wherein the topical formulation is to be administered for at least 12 weeks.

14. The use of claim 4, wherein the topical formulation is a cream formulation.

15. The use of claim 1, wherein the medicament is to be administered such that the subject achieves an IGA score of 0 or 1 with 2: 2 grade improvement from baseline.

16. The use of claim 1, wherein the medicament is to be administered such that the subject achieves an improvement in a subject's response to Itch NRS from baseline.

17. The use of claim 1, wherein the medicament is to be administered such that the subject achieves about a 5%, about a 10%, about a 20%, about a 30%, about a 40%, about a 50%, about a 60%, about a 70%, about a 80%, about a 90%, or about a 95% improvement in a subject's response to Itch NRS from baseline.

18. The use of claim 1, wherein the medicament is to be administered such that the subject achieves about a 5%, about a 10%, about a 20%, about a 30%, about a 40%, about a 50%, about a 60%, about a 70%, about a 80%, about a 90%, or about a 95% improvement in a subject's response in Prurigo Activity Score (PAS) from baseline.

19. The use of claim 1, wherein the medicament is to be administered such

that the subject achieves about a 5%, about a 10%, about a 20%, about a 30%, about a 40%, about a 50%, about a 60%, about a 70%, about a 80%, about a 90%, or about a 95% improvement in a subject's response in Itchy Quality of Life (Itchy QoL) from baseline.

20. The use of claim 1, wherein the medicament is to be administered such that the subject achieves about a 5%, about a 10%, about a 20%, about a 30%, about a 40%, about a 50%, about a 60%, about a 70%, about a 80%, about a 90%, or about a 95% improvement in a subject's response in Dynamic Pruritus Score (DPS) from baseline.

21. The use of claim 1, wherein the medicament is to be administered such that the subject achieves about a 5%, about a 10%, about a 20%, about a 30%, about a 40%, about a 50%, about a 60%, about a 70%, about a 80%, about a 90%, or about a 95% improvement in a subject's response to DLQI from baseline.

22. The use of claim 1, wherein the subject has an itch Numerical Rating Scale of at least 4 at baseline.

23. The use of claim 1, wherein the subject is aged 18 or older.

24. The use of claim 1, wherein the ruxolitinib, or pharmaceutically acceptable salt thereof, is to be administered in combination with a further therapeutic agent.